UK markets open in 3 hours 36 minutes

Lisata Therapeutics, Inc. (0HS8.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
2.8900-0.2000 (-6.47%)
At close: 02:33PM BST
Full screen
Previous close3.0900
Open0.0000
Bid0.0000 x N/A
Ask0.0000 x N/A
Day's range0.0000 - 0.0000
52-week range
Volume24
Avg. volume401
Market capN/A
Beta (5Y monthly)1.07
PE ratio (TTM)N/A
EPS (TTM)-0.3940
Earnings date07 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Zacks

    Lisata's (LSTA) LSTA1 Gets FDA Orphan Drug Tag for Osteosarcoma

    The FDA bestows an Orphan Drug designation to Lisata's (LSTA) lead investigational product candidate, LSTA1, for the treatment of osteosarcoma. Stock rises.

  • GlobeNewswire

    Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

    BASKING RIDGE, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that the U.S. Food and Drug Administration (the “FDA”) has granted Orphan Drug Designation (“ODD”) to LSTA1, the Company’s lead product candidate, for the treatment of osteosarcoma, a rare cancer that can develop in

  • GlobeNewswire

    Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

    BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced that David J. Mazzo, PhD, President and Chief Executive Officer of Lisata, will participate in the following events in April: LD Micro Invitational XIV (April 8-9, 2024) Format: In-person and On-demandLocation: Sofi